Designation Provides Patients with Access to Latest CF Treatments
The Cystic Fibrosis Center at Sanford USD Medical Center has been nationally recognized by Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), an affiliate of the Cystic Fibrosis Foundation, as a Therapeutics Development Center (TDC) site. This designation provides cystic fibrosis (CF) patients at Sanford access to the latest in CF treatment research through the Therapeutics Development Network (TDN), a specialized network of research centers throughout the country. Such access is only available to accredited Cystic Fibrosis Centers with Therapeutic Development Center designation.
This designation also brings a $64,800 grant to the Cystic Fibrosis Center at Sanford. The grant funds will be used to provide patients access to pharmaceutical clinical trials and new medications. This access will help develop new methods and treatments needed for continued progress toward a cure for patients with CF not only at Sanford, but throughout the world. The expansion of TDN sites will help ensure an adequate patient base and a critical mass of highly trained personnel in the area of clinical research to conduct CF studies.
“This program will allow us to offer opportunities for our patients with cystic fibrosis to participate in trials of new therapies and medications which could ultimately improve the quality of patient’s lives. The increased access to new treatments and research could lead to discoveries that improve the quality of life for all patients with cystic fibrosis,” said James Wallace, MD, Program Director, Cystic Fibrosis Center at Sanford. Added Preston W. Campbell, III, M.D., Executive Vice President of Medical Affairs for the Cystic Fibrosis Foundation, “We congratulate the Cystic Fibrosis Center at Sanford on joining a network of excellent clinical trial facilities nationwide. These centers will help CF drugs move more swiftly from the research and testing stage into the hands of patients who need them, and expand the therapies available for fighting this devastating disease.”
Cystic fibrosis (CF) is a life-threatening genetic disease that affects more than 30,000 children and adults in the U.S and 70,000 people worldwide. It affects the lungs and digestive system and makes people who have it vulnerable to repeated lung infections that can be fatal. Now, thanks to dramatic advances in drug discovery and care fueled by the Cystic Fibrosis Foundation, the median age of survival for people with CF has doubled in the past 25 years and is currently more than 37 years. Children born with CF can look forward to longer and more comfortable lives. In the last ten years, research into all aspects of CF has helped doctors to understand the illness better and to develop new therapies.
South Dakota Cystic Fibrosis Center at Sanford
The South Dakota Cystic Fibrosis Center located at Sanford Children’s Specialty Clinic is the only accredited CF Center in South Dakota. It takes a multidisciplinary approach to the care of children and adults with cystic fibrosis. The center consists of numerous specialists who work together to provide care for each patient. The interdisciplinary team of pediatric pulmonologists James Wallace, MD, (Center Director and Pediatric Program Director) and Matthew C. Lundien, MD, adult pumonologists David Thomas, MD (Adult Program Director) and Susan Rohr, DO, and clinical pharmacist Stacy Peters, PharmD, registered nurses, respiratory therapists, social workers and dieticians forms the core of our center and meets regularly to assess the clinical, educational and psychosocial needs of each family and to plan and evaluate care provided.